AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 15105105
Drug: Lopinavir-ritonavir at
RxNorm normalized name: lopinavir / ritonavir
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lopinavir-ritonavir at 800/200 mg BID (arm 1)
Trial: 15105105
Drug: Lopinavir-ritonavir at
RxNorm normalized name: lopinavir / ritonavir
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lopinavir-ritonavir at 400/400 mg BID (arm 2)
Trial: 15105105
Drug: Rifampin at
RxNorm normalized name: Rifampin
DrugBank: Rifampin (DB01045)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rifampin at 600 mg once daily
Trial: 10955700
Drug: Inhaled budesonide
RxNorm normalized name: budesonide Inhalation Suspension
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled budesonide (100 or 200 microg daily)
Trial: 9101424
Drug: 4 g/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 g/day of an 85% concentrate of the ethyl esters of eicosapentenoic and docosahexaenoic acids for 6 weeks
Trial: 9101424
Drug: 4 g/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 g/day of ethyl esters of corn oil fatty acids
Trial: 9101424
Drug: 4 g/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 g/day of an 85% concentrate of the ethyl esters of eicosapentenoic and docosahexaenoic acids
Trial: 8250314
Drug: Flumazenil 3
RxNorm normalized name: Flumazenil
DrugBank: Flumazenil (DB01205)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Flumazenil 3 mg
Trial: 8267193
Drug: Flumazenil (1
RxNorm normalized name: Flumazenil (18-F)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flumazenil (1 mg and 3 mg)
Trial: 2860156
Drug: Local, intra-operative
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Local, intra-operative administration of povidone-iodine
Trial: 2860156
Drug: Prophylactic antibiotic
RxNorm normalized name: polylactic acid-polyglycolic acid copolymer
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prophylactic antibiotic therapy
Trial: 3113246
Drug: Misoprostol, 800
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Misoprostol, 800 micrograms to 1,200 micrograms daily in four to six divided doses, for periods of from one day to 17 months.
Trial: 31190495
Drug: Biological feedback
RxNorm normalized name: beremagene geperpavec
DrugBank: Beremagene geperpavec (DB17831)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Biological feedback training of pelvic floor muscle
Trial: 27750353
Drug: Intensive diabetes
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intensive diabetes screening and treatment program in Ward-A
Trial: 27750353
Drug: Standard treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard treatment in Ward-B
Trial: 24667938
Drug: Daily oral
RxNorm normalized name: GEMTESA 75 MG Once-Daily Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily oral tenofovir
Trial: 15050085
Drug: Combined psychotherapy
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined psychotherapy and pharmacotherapy for depression
Trial: 10652955
Drug: Pamidronate (APD)
DrugBank: Pamidronic acid (DB00282)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pamidronate (APD) 30 mg i.v. in 500 ml D5W over 4 hours
Trial: 9284985
Drug: Active treatment
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active treatment with extracts of Dermatophagoides pteronyssinus (Dpt) or D. farinae (Dfa) (Alutard SQ, ALK, Denmark)
Trial: 24521021
Drug: calcineurin inhibitor
RxNorm normalized name: Calcineurin inhibitor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: calcineurin inhibitor
Trial: 23750536
Drug: Glutamate supplement
RxNorm normalized name: glutamate
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Glutamate supplement + carbohydrate drink (GLU+CHO)
Trial: 23750536
Drug: Glutamate supplement
RxNorm normalized name: glutamate
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Glutamate supplement + placebo drink (GLU)
Trial: 23750536
Drug: Placebo supplement
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo supplement + carbohydrate drink (CHO)
Trial: 23750536
Drug: Placebo supplement
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo supplement + placebo drink (CON)
Trial: 18609122
Drug: 50 mg
RxNorm normalized name: talc 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg ranitidine as a bolus intravenously
Trial: 14697932
Drug: Cap Arpimune
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cap Arpimune ME (test formulation)
Trial: 14697932
Drug: Cap Sandimmune
RxNorm normalized name: cyclosporine Oral Capsule [Sandimmune]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cap Sandimmune Neoral (reference formulation)
Trial: 3924617
Drug: Transdermal nitroglycerin
RxNorm normalized name: nitroglycerin Transdermal System
DrugBank: Nitroglycerin (DB00727)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transdermal nitroglycerin system (TNS) 20 cm2 or greater
Trial: 3924617
Drug: Transdermal nitroglycerin
RxNorm normalized name: nitroglycerin Transdermal System
DrugBank: Nitroglycerin (DB00727)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transdermal nitroglycerin system (TNS) 10 cm2
Trial: 29954713
Drug: 3 weekly
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 3 weekly stage-tailored messages on healthful behaviors for 10 weeks; and 3 monthly stage-tailored messages and 1 monthly e-mail encouraging a visit to the portal page after the 3-month physical assessment
Trial: 26784939
Drug: Talinolol 50
RxNorm normalized name: talinolol 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Talinolol 50 mg tablet (oral administration)
Trial: 26016363
Drug: Ligustrazine treatment
RxNorm normalized name: ligustrazine
DrugBank: Ligustrazine (DB19074)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ligustrazine treatment (80 mg/d; i.v.; for 2 weeks) in addition to standard treatment
Trial: 26016363
Drug: Standard treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard treatment with antibiotics, antiasthmatic and expectorant medications, and oxygenation
Trial: 21862953
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy with intravitreal ranibizumab and topical bromfenac
Trial: 11125353
Drug: Temporary inactivation
RxNorm normalized name: diphtheria toxoid vaccine, inactivated / tetanus toxoid vaccine, inactivated Injection [Tdvax]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Temporary inactivation of sacral nerve stimulation therapy
Trial: 9743652
Drug: Combination Treatment
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination Treatment (TPs and scanner technique)
Trial: 8170098
Drug: Peribulbar anesthesia
RxNorm normalized name: Gelato Anesthetic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Peribulbar anesthesia (PERI) with 6, 8 or 10 ml of bupivacaine-lidocaine-hyaluronidase mixture
Trial: 8170098
Drug: Retrobulbar anesthesia
RxNorm normalized name: Gelato Anesthetic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Retrobulbar anesthesia (RETRO) using Unsold technique with 5 ml of bupivacaine-lidocaine-hyaluronidase mixture and Nadbath/Rehman facial nerve block (5 ml etidocaine-lidocaine mixture)
Trial: 28929560
Drug: Minocycline (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Minocycline (10 mg/kg intravenous)
Trial: 26518774
Drug: Housing First
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Housing First plus Assertive Community Treatment
Trial: 22235821
Drug: Furosemide (60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Furosemide (60 mg)
Trial: 22235821
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of furosemide and hydrochlorothiazide
Trial: 17131317
Drug: antiCagA antibodies
RxNorm normalized name: digoxin antibodies Fab fragments Injection [DigiFab]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: antiCagA antibodies
Trial: 17131317
Drug: Severe chronic
RxNorm normalized name: Chromic Chloride
DrugBank: Chromic chloride (DB09129)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Severe chronic atrophic gastritis (SCAG) defined as PGA <22 microg/l
Trial: 15878384
Drug: Generic warfarin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Generic warfarin sodium product
Trial: 15878384
Drug: Branded warfarin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Branded warfarin sodium product
Trial: 12186116
Drug: Group A
RxNorm normalized name: Blood group A IgM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group A (Insulin only, 50 patients)
Trial: 12186116
Drug: Group B
RxNorm normalized name: Blood group B IgM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group B (Insulin + GBC 20 mg/day, 49 patients)
Trial: 12186116
Drug: Group C
RxNorm normalized name: STREPTOCOCCUS ANTIGEN (GROUP C)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group C (Morning insulin + GBC 20 mg/day, 43 patients)
Trial: 12186116
Drug: Group D
RxNorm normalized name: Prostaglandin group D
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group D (Evening insulin + GBC 20 mg/day, 46 patients)
Trial: 1773076
Drug: Air caloric
RxNorm normalized name: air
DrugBank: Medical air (DB09337)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Air caloric irrigation at 8 L/min for 45 seconds
Trial: 1773076
Drug: Air caloric
RxNorm normalized name: air
DrugBank: Medical air (DB09337)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Air caloric irrigation at 8 L/min for 60 seconds
Trial: 1773076
Drug: Air caloric
RxNorm normalized name: air
DrugBank: Medical air (DB09337)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Air caloric irrigation at 8 L/min for 75 seconds
Trial: 1773076
Drug: Air caloric
RxNorm normalized name: air
DrugBank: Medical air (DB09337)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Air caloric irrigation at 8 L/min for 10-beat and 10-sec measurements
Trial: 6752558
Drug: Protocol A:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Protocol A: 6‐MP (50 mg/m2) p.o. daily + MTX (20‐30 mg/m2) p.o. weekly
Trial: 6752558
Drug: Protocol B:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Protocol B: 6‐MP (50 mg/m2) p.o. daily + MTX (75‐150 mg/m2) i.v. every two weeks
Trial: 6752558
Drug: Protocol C:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Protocol C: 6‐MP (50 mg/m2) p.o. daily + alternating 8‐week-courses of four biweekly i.v. injections of MTX (75‐150 mg/m2) and four biweekly i.v. injections of Cyclo (600 mg/m2)
Trial: 31432689
Drug: Neratinib-based therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neratinib-based therapy
Trial: 26027861
Drug: 0.2 ml
RxNorm normalized name: isopropyl alcohol 0.2 ML/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.2 ml 0.8% Hyaluronic Acid (HA) applied immediately after surgery
Trial: 26027861
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no treatment applied)
Trial: 23044704
Drug: Extracorporeal shock
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Extracorporeal shock wave therapy (ESWT) - 1000 shots at maximal tolerable intensity
Trial: 23044704
Drug: Local corticosteroid
RxNorm normalized name: Corticosteroids acting locally
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Local corticosteroid (CS) injection
Trial: 19851160
Drug: Injection phase
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Injection phase
Trial: 17069488
Drug: Low-level laser
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-level laser therapy (LLLT) with 685-nm wavelength, output power of 50 mW, energy density of 4 J/cm².
Trial: 2528969
Drug: zidovudine 600
RxNorm normalized name: Zidovudine
DrugBank: Zidovudine (DB00495)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: zidovudine 600 mg/day for 18 weeks
Trial: 2528969
Drug: zidovudine 900
RxNorm normalized name: Zidovudine
DrugBank: Zidovudine (DB00495)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: zidovudine 900 mg/day for 9 weeks
Trial: 2528969
Drug: zidovudine 1200
RxNorm normalized name: Zidovudine
DrugBank: Zidovudine (DB00495)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: zidovudine 1200 mg/day for 9 weeks
Trial: 2528969
Drug: zidovudine 1200
RxNorm normalized name: Zidovudine
DrugBank: Zidovudine (DB00495)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: zidovudine 1200 mg/day or highest tolerated dose at 8-hourly intervals after washout
Trial: 2528969
Drug: zidovudine 600
RxNorm normalized name: Zidovudine
DrugBank: Zidovudine (DB00495)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: zidovudine 600 mg/day
Trial: 2528969
Drug: zidovudine 900
RxNorm normalized name: Zidovudine
DrugBank: Zidovudine (DB00495)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: zidovudine 900 mg/day
Trial: 2528969
Drug: zidovudine 1200
RxNorm normalized name: Zidovudine
DrugBank: Zidovudine (DB00495)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: zidovudine 1200 mg/day
Trial: 1252882
Drug: Cotrimoxazole 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cotrimoxazole 2 tablets twice daily
Trial: 1252882
Drug: Cephalexin 1
RxNorm normalized name: cephalexin 125 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cephalexin 1 g twice daily
Trial: 25263498
Drug: Single dose
RxNorm normalized name: Citrucel Single Dose Packets (Orange)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose of ampicillin and metronidazole
Trial: 25263498
Drug: Multiple-day regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multiple-day regimen of ampicillin/amoxicillin and metronidazole
Trial: 22072853
Drug: Activated Dimethicone
RxNorm normalized name: Activated dimethicone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Activated Dimethicone plus water (up to 100 mL)
Trial: 22072853
Drug: N-acetylcysteine (NAC)
DrugBank: Acetylcysteine (DB06151)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: N-acetylcysteine (NAC) plus water (up to 100 mL)
Trial: 22072853
Drug: Activated Dimethicone
RxNorm normalized name: Activated dimethicone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Activated Dimethicone and NAC plus water (up to 100 mL)
Trial: 22072853
Drug: Water alone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Water alone (100 mL)
Trial: 19153339
Drug: Topical tretinoin,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical tretinoin, 0.1%, applied twice daily to the face and ears
Trial: 19153339
Drug: Vehicle control
RxNorm normalized name: meningococcal group B vaccine / Neisseria meningitidis serogroup B recombinant FHBP fusion protein antigen / Neisseria meningitidis serogroup B recombinant NHBA fusion protein antigen / Neisseria meningitidis serogroup B strain NZ98/254 outer membrane vesicle Prefilled Syringe [Bexsero]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vehicle control cream, applied twice daily to the face and ears
Trial: 12770652
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg of nifedipine intranasally delivered
Trial: 8886294
Drug: Cocaine hydrochloride
RxNorm normalized name: Cocaine Hydrochloride
DrugBank: Cocaine (DB00907)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cocaine hydrochloride 0.3 mg/kg intravenously
Trial: 2552868
Drug: Dexamethasone isonicotinate
RxNorm normalized name: Dexamethasone isonicotinate
DrugBank: Dexamethasone isonicotinate (DB11487)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexamethasone isonicotinate (four puffs bid for seven days, ie, 0.5 mg bid for seven days; last four puffs 30 minutes before TDI)
Trial: 31739245
Drug: Low-dose dopamine
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose dopamine (2 μg·kg-1·min-1)
Trial: 21705157
Drug: Saline injection
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Saline injection (3 mL)
Trial: 21705157
Drug: Autologous blood
RxNorm normalized name: Banked autologous blood
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Autologous blood injection (3 mL)
Trial: 21705157
Drug: Corticosteroid injection
RxNorm normalized name: CORTICOSTEROIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Corticosteroid injection (3 mL)
Trial: 9311397
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (received allogeneic red cells if hemoglobin < 5 mmol/L)
Trial: 8456428
Drug: Intravenous infusion
RxNorm normalized name: intravenous infusion pump accessory
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous infusion of hirulog (0.6 mg kg-1 h-1 for 2 h)
Trial: 8456428
Drug: Intravenous infusion
RxNorm normalized name: intravenous infusion pump accessory
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous infusion of hirulog
Trial: 8456428
Drug: Subcutaneous injection
RxNorm normalized name: EPINEPHRINE 0.3 mg SUBCUTANEOUS INJECTION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous injection of hirulog
Trial: 8456428
Drug: Intravenous hirulog
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous hirulog
Trial: 26924770
Drug: Targeted therapies
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Targeted therapies for metastatic renal cell carcinoma
Trial: 22340541
Drug: Fish oil
RxNorm normalized name: Fish oil
DrugBank: Fish oil (DB13961)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fish oil (0.2 g/kg) and soybean oil (1.0 g/kg)
Trial: 22340541
Drug: Soybean oil
RxNorm normalized name: Soybean Oil
DrugBank: Soybean oil (DB09422)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Soybean oil (1.2 g/kg)
Trial: 1674231
Drug: 75 mg
RxNorm normalized name: talc 75 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 75 mg of roxatidine acetate at night
Trial: 6223699
Drug: Etodolac (mean
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Etodolac (mean daily dose: 319 mg)
Trial: 6223699
Drug: Aspirin (mean
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin (mean daily dose: 4,701 mg)
Trial: 24329972
Drug: Extended cognitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Extended cognitive behavioral therapy
Trial: 24329972
Drug: Standard cessation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard cessation treatment without extended cognitive behavioral therapy
Trial: 24329972
Drug: Extended nicotine
RxNorm normalized name: Nicotine
DrugBank: Nicotine (DB00184)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Extended nicotine replacement therapy
Trial: 15270789
Drug: Pioglitazone (initially
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pioglitazone (initially 30 mg QD, titrated to 45 mg)
Trial: 15270789
Drug: Glibenclamide (initially
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glibenclamide (initially 1.75 mg QD, titrated to 10.5 mg)
Trial: 11172962
Drug: Group A:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group A: 10 x 3 Gy (total dose, 30 Gy) in 2 series (5 x 3Gy) separated by 8 weeks
Trial: 11172962
Drug: Group B:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group B: 7 x 3 Gy (total dose, 21 Gy) in 1 series within 2 weeks
Trial: 8083702
Drug: Investigational therapies
RxNorm normalized name: Theraplex Eczema Therapy
DrugBank: Colloidal oatmeal (DB11286)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Investigational therapies in adjuvant therapy RCTs (14 of 90 RCTs)
Trial: 8083702
Drug: Investigational therapies
RxNorm normalized name: Theraplex Eczema Therapy
DrugBank: Colloidal oatmeal (DB11286)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Investigational therapies in advanced-disease therapy RCTs (3 of 141 RCTs)
Trial: 8083702
Drug: Dose-intensity with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dose-intensity with blood-product support trials
Trial: 28082211
Drug: Glycerin suppositories
RxNorm normalized name: Glycerin Suppositories
DrugBank: Glycerin (DB09462)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glycerin suppositories every 8 hours during phototherapy
Trial: 28082211
Drug: No glycerin
RxNorm normalized name: Glycerin
DrugBank: Glycerin (DB09462)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No glycerin suppositories (sham group)
Trial: 19655226
Drug: Glycerin suppositories
RxNorm normalized name: Glycerin Suppositories
DrugBank: Glycerin (DB09462)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glycerin suppositories
Trial: 18768369
Drug: Anastrozole (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anastrozole (1 mg/day for 5 years)
Trial: 16361368
Drug: Phytoestrogens (resveratrol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phytoestrogens (resveratrol and genistein) and selective estrogen receptor-alpha agonist (PPT)
Trial: 30067289
Drug: Telemetric gas-sensing
RxNorm normalized name: Kaolin 45.5 g in 130 g TOPICAL CREAM [SONATURAL THE PURE PORE TENSING CARBONIC BUBBLE POP CLAY MASK]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Telemetric gas-sensing capsule (1.25-40 g inulin)
Trial: 30067289
Drug: Telemetric gas-sensing
RxNorm normalized name: Kaolin 45.5 g in 130 g TOPICAL CREAM [SONATURAL THE PURE PORE TENSING CARBONIC BUBBLE POP CLAY MASK]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Telemetric gas-sensing capsule (20 or 40 g glucose)
Trial: 25948727
Drug: IV bolus
RxNorm normalized name: SET,INFUSION,BOLUS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV bolus injection of 2.0 mg/kg cyclosporine
Trial: 23418886
Drug: Web-based guided
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Web-based guided self-help course (6 weekly lessons with weekly support from a coach)
Trial: 23418886
Drug: Care-as-usual (no
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Care-as-usual (no additional treatment)
Trial: 18254985
Drug: Carrot juice
RxNorm normalized name: carrot juice
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carrot juice (330 ml per day for 2 weeks)